Viking Therapeutics/$VKTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Ticker
- $VKTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 74
- Headquarters
- San Diego, United States
- Website
- www.vikingtherapeutics.com
VKTX Metrics
BasicAdvanced
$3.5B
-
-$5.41
0.65
-
Price and volume
Market cap
$3.5B
Beta
0.65
52-week high
$43.10
52-week low
$23.82
Average daily volume
4.7M
Financial strength
Current ratio
7.267
Quick ratio
7.168
Long term debt to equity
0.433
Total debt to equity
0.433
Interest coverage (TTM)
-7,370.14%
Profitability
Management effectiveness
Return on assets (TTM)
-47.23%
Return on equity (TTM)
-96.37%
Valuation
Price to book
5.98
Price to tangible book (TTM)
5.98
Price to free cash flow (TTM)
-6.914
Free cash flow yield (TTM)
-14.46%
Free cash flow per share (TTM)
-3.989
Growth
Earnings per share change (TTM)
155.14%
3-year earnings per share growth (CAGR)
80.90%
10-year earnings per share growth (CAGR)
15.41%
What the Analysts think about VKTX
Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.
Analyst projections of the future price of Viking Therapeutics stock.
Bulls say / Bears say
In a small exploratory arm, weekly VK2735 produced 21.7% weight loss after 33 weeks, with no plateau observed. That offers an encouraging early signal for the lead injectable programme, though it still needs confirmation in larger trials. (Viking Therapeutics)
After weekly induction, participants retained up to 97% of their weight loss on every-other-week dosing and up to 90% on monthly dosing; gastrointestinal side effects during maintenance were similar to placebo. Less frequent dosing could make long-term treatment more convenient. (Reuters, Viking Therapeutics)
The oral tablet cut body weight by up to 12.2% over 13 weeks in Phase 2, and Viking has now started two Phase 3 oral trials. Success could give the company both a tablet and an injection option for obesity treatment. (Viking Therapeutics, Viking Therapeutics)
The headline maintenance result came from a study of about 180 people and used exploratory weight measures; the larger injectable Phase 3 trials are still testing treatment over 78 weeks. The lead programme therefore still faces meaningful clinical risk before its efficacy is established in pivotal studies. (Viking Therapeutics, Viking Therapeutics)
VK2735 would enter a market where Lilly and Novo already sell oral and injectable obesity medicines, while both are advancing further candidates. Their scale and established products could make it hard for Viking to win a substantial share even if its trials succeed. (Yahoo Finance)
Viking's September financing included $275 million in new shares and $225 million in convertible notes, creating dilution and potential further dilution if the notes convert. At the same time, quarterly R&D costs nearly doubled year on year to $115.8 million, reflecting the expense of advancing its trials. (The Motley Fool, Viking Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
VKTX Financial Performance
Revenues and expenses
VKTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
VKTX News
AllArticlesVideos
Funds containing VKTX
Fund name | Fund size | $VKTX weighting |
|---|---|---|
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $2.7B | 0.05% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
iShares MSCI World Small Cap€IUSN | $9B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.